연구용
제품 번호: S2618
| 세포주 | 분석 유형 | 농도 | 배양 시간 | 제형 | 활성 설명 | PMID |
|---|---|---|---|---|---|---|
| C2C12 | Kinase Assay | inhibits the kinase activity of ALK4 and ActRIIA with IC50 values of 101 and 210 nm, respectively | 25368322 | |||
| EOC216 | Growth Inhibition Assay | 0.1-10 μM | 2-10 d | DMSO | induce cell death in a dose-dependent manner | 25227893 |
| OVAC429 | Growth Inhibition Assay | 2/5 μM | 48 h | DMSO | decreases the percentage of cells in S phas | 25227893 |
| SKOV3 | Growth Inhibition Assay | 2/5 μM | 48 h | DMSO | decreases the percentage of cells in S phas | 25227893 |
| OVCA429 | Growth Inhibition Assay | 2/5 μM | 48 h | DMSO | decreases the percentage of cells in S phas | 25227893 |
| EOC219 | Growth Inhibition Assay | 2/5 μM | 48 h | DMSO | decreases the percentage of cells in S phas | 25227893 |
| A549 | Growth Inhibition Assay | 0.5-16 μM | DMSO | inhibits cell growth in a dose-dependent manner | 24778011 | |
| BEAS-2B | Growth Inhibition Assay | 0.5-16 μM | DMSO | inhibits cell growth in a dose-dependent manner | 24778011 | |
| hBMSCs | Function Assay | 0.2 μM | 7 d | abolishes the silibinin-promoted ALP activity partly | 24076187 | |
| PANC-1 | Growth Inhibition Assay | 5-500 nM | 48 h | inhibits cell growth in a dose-dependent manner | 23969729 | |
| MIA PaCa-2 | Growth Inhibition Assay | 5-500 nM | 48 h | inhibits cell growth in a dose-dependent manner | 23969729 | |
| Bx-PC3 | Growth Inhibition Assay | 5-500 nM | 48 h | inhibits cell growth in a dose-dependent manner | 23969729 | |
| PC3 | Function Assay | 500 nM | 2 h | represses activation of Smad1/5/8 and P-Smad3 levels | 22452883 | |
| LNCaP | Function Assay | 0–500 nM | 2 h | reverses rapamycin-induced cell death | 22452883 | |
| EOC | Function Assay | 10-1000 nM | 72 h | reduces the phosphorylated BMP R-Smad1/5/8 | 22249415 | |
| HaCaT | Function Assay | 0.001-10 μM | 2 h | inhibits BMP2-induced phosphorylation of Smad1/5/8 with an IC50 of ~0.005 μM | 21740966 | |
| HaCaT | Function Assay | 0.001-10 μM | 2 h | inhibits the ability of ALK2 to phosphorylate GST-Smad1 with an IC50 of 45 nM | 21740966 | |
| HaCaT | Function Assay | 0.001-10 μM | 2 h | inhibits the ability of ALK3 to phosphorylate Smad1 with an IC50 of 100 nM | 21740966 | |
| HaCaT | Function Assay | 0.001-10 μM | 2 h | inhibits ALK4 and ALK5 with IC50 values of 0.3 μM and 0.5 μM respectively | 21740966 | |
| C2C12 | Function assay | 30 mins | Inhibition of BMP6-induced ALK2 transcriptional activity in mouse C2C12 cells expressing BRE-Luc after 30 mins by luciferase reporter gene assay, EC50 = 0.014 μM. | 30227946 | ||
| BT-12 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells | 29435139 | |||
| fibroblast cell | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells | 29435139 | |||
| Rh30 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells | 29435139 | |||
| KB-3-1 | Function assay | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 31515284 | |||
| C2C12 | Function assay | 0.1 uM | Inhibition of ALK5 in mouse C2C12 cells assessed as decrease in TGFbeta1-induced Smad1/5 phosphorylation at 0.1 uM by Western blot method | 28103025 | ||
| 클릭하여 더 많은 세포주 실험 데이터 보기 | ||||||
| 분자량 | 406.48 | 화학식 | C25H22N6 |
보관 (수령일로부터) | |
|---|---|---|---|---|---|
| CAS 번호 | 1062368-24-4 | SDF 다운로드 | 원액 보관 |
|
|
| 동의어 | DM3189 | Smiles | C1CN(CCN1)C2=CC=C(C=C2)C3=CN4C(=C(C=N4)C5=CC=NC6=CC=CC=C56)N=C3 | ||
|
In vitro |
0.01M HCl : 2.5 mg/mL
DMSO
: Insoluble
Water : Insoluble |
|
In vivo |
|||||
1단계: 아래 정보 입력 (권장: 실험 중 손실을 고려하여 추가 동물 포함)
2단계: 생체 내 제형 입력 (이것은 계산기일 뿐 제형이 아닙니다. 용해도 섹션에 생체 내 제형이 없는 경우 먼저 당사에 문의하십시오.)
계산 결과:
작업 농도: mg/ml;
DMSO 원액 준비 방법: mg 약물 사전 용해 μL DMSO ( 원액 농도 mg/mL, 농도가 해당 약물 배치의 DMSO 용해도를 초과하는 경우 먼저 당사에 문의하십시오. )
생체 내 제형 준비 방법: 취하다 μL DMSO 원액, 다음 추가μL PEG300, 혼합하고 투명하게 한 다음 추가μL Tween 80, 혼합하고 투명하게 한 다음 추가 μL ddH2O, 혼합하고 투명하게 합니다.
생체 내 제형 준비 방법: 취하다 μL DMSO 원액, 다음 추가 μL 옥수수 기름, 혼합하고 투명하게 합니다.
참고: 1. 다음 용매를 추가하기 전에 액체가 투명한지 확인하십시오.
2. 용매를 순서대로 추가해야 합니다. 다음 용매를 추가하기 전에 이전 추가에서 얻은 용액이 투명한 용액인지 확인해야 합니다. 와동, 초음파 또는 뜨거운 물 중탕과 같은 물리적 방법을 사용하여 용해를 도울 수 있습니다.
| Targets/IC50/Ki |
ALK1
(Cell-free assay) 0.8 nM
ALK2
(Cell-free assay) 0.8 nM
ALK3
(Cell-free assay) 5.3 nM
ALK6
(Cell-free assay) 16.7 nM
|
|---|---|
| 시험관 내(In vitro) |
LDN193189 potently inhibits BMP4-mediated Smad1, Smad5 and Smad8 activation with IC50 of 5 nM, and efficiently inhibits transcriptional activity of the BMP type I receptors ALK2 and ALK3 with IC50 of 5 nM and 30 nM, respectively. Furthermore, this compound also shows the inhibitory effect on the transcriptional activity induced by either constitutively active ALK2R206H or ALK2Q207D mutant proteins. A recent study shows that this chemical blocks the production of reactive oxygen species induced by oxidized LDL during atherogenesis in human aortic endothelial cells. |
| 키나아제 분석 |
Alkaline phosphatase activity
|
|
C2C12 cells are seeded into 96-well plates at 2,000 cells per well in DMEM supplemented with 2% FBS. The wells are treated in quadruplicate with BMP ligands and LDN-193189 or vehicle. The cells are collected after 6 days in culture in 50 μL Tris-buffered saline and 1% Triton X-100. The lysates are added to p-nitro-phenylphosphate reagent in 96-well plates for 1 hours and then evaluated alkaline phosphatase activity (absorbance at 405 nm). Cell viability and quantity are measured by Cell Titer Aqueous One (absorbance at 490 nm), using replicate wells treated identically to those used for alkaline phosphatase measurements.
|
|
| 생체 내(In vivo) |
In conditional caALK2-transgenic mice with Ad.Cre on on postnatal day 7 (P7), LDN-193189 (3 mg/kg i.p) leads to mild calcifications surrounding the left tibia and fibula first visible at P13, and prevents radiographic lesions at P15 without causing weight loss or growth retardation, spontaneous fractures, decreased bone density or behavioral abnormalities. This compound dorsalizes zebrafish embryos by inhibiting signaling pathways induced by bone morphogenetic protein (BMP)6 without effect on vascular development. In PCa-118b tumor-bearing mice, this chemical treatment attenuates tumor growth and reduces bone formation in the tumors. In LDL receptor-deficient (LDLR-/-) mice, this agent potently inhibits development of atheroma. Moreover, it also exhibits the inhibitory effects on associated vascular inflammation, osteogenic activity, and calcification. |
참조 |
|
| 방법 | 바이오마커 | 이미지 | PMID |
|---|---|---|---|
| Western blot | pSMAD1 / pSMAD5 / pSMAD8 / SMAD1 / SMAD5 / SMAD8 / ID1 / SMAD4 / PARP / Cleaved PARP |
|
31098401 |
| Immunofluorescence | Tbx18 / Hcn4 |
|
30906456 |
| Growth inhibition assay | Cell viability |
|
31098401 |